Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002458 · ClinicalTrials.gov registry record · Phase 2
Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00002458: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00002458 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002458, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating children with metastatic neuroblastoma in second remission.
Interventions
- BIOLOGICAL monoclonal antibody 3F8
Trial Details
| Field | Value |
|---|---|
| Start Date | 1987-11 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002458
The ClinicalTrials.gov registry entry for NCT00002458 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which monoclonal antibody 3F8 is the first listed.
NCT00002458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002458 about?
NCT00002458 is a clinical study titled "Monoclonal Antibody Therapy in Treating Children With Metastatic Neuroblastoma in Second Remission". RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of monoclonal antibody in treating children with metastatic neuroblastoma in second remission.
What is the current status of trial NCT00002458?
This trial is currently completed. It is a Phase 2 study. The study started on 1987-11. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00002458?
The interventions under investigation include: monoclonal antibody 3F8 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002458?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.